Nof E, Kutyifa V, McNitt S, et al. - Among 1,804 patients registered in MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy), researchers examined the link between the CHA₂DS₂-VASc score (dichotomized as high at the upper quartile [≥ 5] and further evaluated as a continuous measure) and the risk of ventricular tachyarrhythmia (VTA) and mortality, to ultimately determine if multiple cardiovascular comorbidities, included in the CHA₂DS₂-VASc score, may be of use in the evaluation of VTAs and death risk in heart failure (HF) patients. According to the findings, the identification of patients with mild HF who exhibit low VTA risk and high morbidity or death risk and may obtain a pronounced clinical benefit from cardiac resynchronization therapy without a defibrillator can be enabled by a high CHA₂DS₂-VASc score. Findings imply that CHA₂DS₂-VASc score may have a role in device adoption among candidates for biventricular pacing.